SEGMENT RESULTS - Schedule of Disaggregation of Revenues (Details) - USD ($)	3 Months Ended								12 Months Ended
	Dec. 31, 2021	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020	Sep. 30, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									$ 2,993,206,000	$ 2,903,074,000	$ 2,914,364,000
Product line revenue reporting threshold	$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000	$ 25,000,000
Total depreciation expense									84,191,000	91,264,000	69,000,000
Corporate unallocated
Disaggregation of Revenue [Line Items]
Total depreciation expense									$ 4,178,000	$ 4,962,000	$ 5,217,000
XIAFLEX® | Revenue from Contract with Customer Benchmark | Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage									14.00%	11.00%	11.00%
VASOSTRICT® | Revenue from Contract with Customer Benchmark | Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage									30.00%	27.00%	18.00%
Branded Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									$ 893,617,000	$ 781,780,000	$ 855,402,000
Branded Pharmaceuticals | Operating segments
Disaggregation of Revenue [Line Items]
Total depreciation expense									10,632,000	11,758,000	12,573,000
Branded Pharmaceuticals | Specialty Products
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									633,150,000	497,078,000	519,676,000
Branded Pharmaceuticals | XIAFLEX®
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									432,344,000	316,234,000	327,638,000
Branded Pharmaceuticals | SUPPRELIN® LA
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									114,374,000	88,182,000	86,797,000
Branded Pharmaceuticals | Other Specialty
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									86,432,000	92,662,000	105,241,000
Branded Pharmaceuticals | Established Products
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									260,467,000	284,702,000	335,726,000
Branded Pharmaceuticals | PERCOCET®
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									103,788,000	110,112,000	116,012,000
Branded Pharmaceuticals | TESTOPEL®
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									43,636,000	35,234,000	55,244,000
Branded Pharmaceuticals | Other Established
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									113,043,000	139,356,000	164,470,000
Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									1,266,097,000	1,238,847,000	1,063,131,000
Sterile Injectables | Operating segments
Disaggregation of Revenue [Line Items]
Total depreciation expense									17,796,000	17,400,000	14,287,000
Sterile Injectables | VASOSTRICT®
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									901,735,000	785,646,000	531,737,000
Sterile Injectables | ADRENALIN®
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									124,630,000	152,074,000	179,295,000
Sterile Injectables | Other Sterile Injectables
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									239,732,000	301,127,000	352,099,000
Generic Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									740,586,000	783,110,000	879,882,000
Generic Pharmaceuticals | Operating segments
Disaggregation of Revenue [Line Items]
Total depreciation expense									47,343,000	52,614,000	32,689,000
International Pharmaceuticals
Disaggregation of Revenue [Line Items]
TOTAL REVENUES, NET									92,906,000	99,337,000	115,949,000
International Pharmaceuticals | Operating segments
Disaggregation of Revenue [Line Items]
Total depreciation expense									$ 4,242,000	$ 4,530,000	$ 4,234,000
International Pharmaceuticals | Revenue from Contract with Customer Benchmark | Product Concentration Risk | Maximum
Disaggregation of Revenue [Line Items]
Concentration risk, percentage									5.00%	5.00%
Colchicine Tablets | Revenue from Contract with Customer Benchmark | Product Concentration Risk | Maximum
Disaggregation of Revenue [Line Items]
Concentration risk, percentage											6.00%